A systematic approach to pharmacotherapy for geriatric major depression

Clinics in Geriatric Medicine

Volumn 30, Issue 3, 2014, Pages 517-534

  Mulsant, Benoit H ^a,b   Blumberger, Daniel M ^a,b   Ismail, Zahinoor ^a,c   Rabheru, Kiran ^d   Rapoport, Mark J ^b,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Algorithm; Antidepressant agents; Drug therapy; Geriatrics; Guidelines; Major depressive disorder; Old age; Stepped care

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LITHIUM SALT; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADVERSE DRUG REACTION; ALGORITHM; CLINICAL EFFECTIVENESS; CONSENSUS; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; GERIATRIC DISORDER; HUMAN; MAJOR DEPRESSION; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOM; TREATMENT RESPONSE; AKATHISIA; ANTICHOLINERGIC SYNDROME; CLINICAL PRACTICE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FOLLOW UP; GERIATRICS; MORNING DOSAGE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PSYCHOTHERAPY; QT PROLONGATION; REMISSION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; AGED; DEPRESSIVE DISORDER, MAJOR;

AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84904416294     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2014.05.002     Document Type: Review

References (86)

1. Olfson M., Marcus S.C. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009, 66(8):848-856.
2. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief; No. 76; 2011. Available at: Accessed April 12, 2014. http://www.cdc.gov/nchs/data/databriefs/db76.pdf.
3. Mojtabai R., Olfson M. National trends in long-term use of antidepressant medications: results from the US National Health and Nutrition Examination Survey. JClin Psychiatry 2014, 75(2):169-177.
4. Kessler R.C., Berglund P., Demler O., National Comorbidity Survey Replication, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
5. Kessler R.C., Birnbaum H., Bromet E., et al. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med 2010, 40(2):225-237.
6. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45.
7. Kirsch I. The emperor's new drugs: exploding the antidepressant myth 2009, The Bodley Head, London.
8. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 12(1):47-53.
9. Fountoulakis K.N., Moller H.J. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011, 12(3):405-412.
10. Vöhringer P.A., Ghaemi S.N. Solving the antidepressant efficacy question: effect sizes in major depressive disorder. Clin Ther 2011, 12:B49-B61.
11. Thase M.E., Larsen K.G., Kennedy S.H. Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 2011, 12:501-507.
12. Gibbons R.D., Hur K., Brown C.H., et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69(6):572-579.
13. Leucht S., Hierl S., Kissling W., et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012, 200:97-106.
14. Undurraga J., Baldessarini R.J. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012, 12(4):851-864.
15. Huedo-Medina T., Johnson B., Kirsch I., et al. Kirsch etal.'s (2008) calculations are correct: reconsidering Fountoulakis & Moller's re-analysis of the Kirsch data. Int J Neuropsychopharmacol 2012, 12:1193-1198.
16. Fountoulakis K.N., Veroniki A.A., Siamouli M., et al. No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. Ann Gen Psychiatry 2013, 12(1):26.
17. Meyers B.S., Sirey J.A., Bruce M., et al. Predictors from early recovery from major depression among people admitted to community-based clinics. Arch Gen Psychiatry 2002, 59:729-735.
18. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry 2002, 159(3):469-473.
19. Zimmerman M., Chelminski I., Posternak M.A. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005, 162(7):1370-1372.
20. Unutzer J., Katon W., Williams J.W., et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care 2001, 39(8):785-799.
21. Unutzer J., Katon W., Callahan C.M., et al. Collaborative care management of late-life depression in the primary care setting. JAMA 2002, 288:2836-2845.
22. Mulsant B.H., Alexopoulos G.S., Reynolds C.F., et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry 2001, 16(6):585-592.
23. Bruce M.L., Ten Have T.R., Reynolds C.F., et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients. JAMA 2004, 291(9):1081-1091.
24. Alexopoulos G.S., Katz I.R., Bruce M.L., et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry 2005, 162:718-724.
25. Alexopoulos G., Reynolds C., Bruce M., the PROSPECT Group, et al. Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT Study. Am J Psychiatry 2009, 166(8):882-890.
26. Tollefson G.D., Bosomworth J.C., Heiligenstein J.H., et al. Adouble-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995, 7(1):89-104.
27. Schneider L.S., Nelson J.C., Clary C.M., Sertraline Elderly Depression Study Group, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003, 160(7):1277-1285.
28. Rapaport M.H., Schneider L.S., Dunner D.L., et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. JClin Psychiatry 2003, 64(9):1065-1074.
29. Roose S.P., Sackeim H.A., Krishnan K.R., Old-Old Depression Study Group, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004, 161(11):2050-2059.
30. Kasper S., de Swart H., Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005, 13(10):884-891.
31. Schatzberg A., Roose S. Adouble-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006, 14(4):361-370.
32. Bose A., Li D., Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008, 16(1):14-20.
33. Raskin J., Wiltse C.G., Siegal A., et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007, 164(6):900-909.
34. Robinson M., Oakes T.M., Raskin J., et al. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry 2014, 22(1):34-45.
35. Posternak M.A., Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 2007, 190:287-292.
36. RutherfordBR, TandlerJ, BrownPJ, etal. Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome. Am J Geriatr Psychiatry, in press. [Epub ahead of print].
37. Gartlehner G., Hansen R.A., Morgan L.C., et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011, 155:772-785.
38. Zimmerman M., Posternak M., Friedman M., et al. Which factors influence psychiatrists' selection of antidepressants?. Am J Psychiatry 2004, 161(7):1285-1289.
39. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (2010 revision). Available at: Accessed April 13, 2014. http://psychiatryonline.org/content.aspx?bookID=28%26sectionID=1667485#654274.
40. Simon G.E., Perlis R.H. Personalized medicine for depression: can we match patients with treatments?. Am J Psychiatry 2010, 167(12):1445-1455.
41. Gartlehner G., Thaler K., Hill S., et al. How should primary care doctors select which antidepressants to administer?. Curr Psychiatry Rep 2012, 14(4):360-369.
42. Thaler K.J., Morgan L.C., Van Noord M., et al. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 2012, 29(6):495-505.
43. Simon G.E., Heiligenstein J.H., Grothaus L., et al. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. JClin Psychiatry 1998, 59(2):49-55.
44. Kocsis J.H., Leon A.C., Markowitz J.C., et al. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. JClin Psychiatry 2009, 70(3):354-361.
45. Remillard A., Blackshaw S., Dangor A. Differential responses to a single antidepressant in recurrent episodes of major depression. Hosp Community Psychiatry 1994, 45:359-361.
46. Steffens D.C., McQuoid D.R., Krishnan K.R. The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach. Psychopharmacol Bull 2002, 36(2):58-68.
47. Whyte E.M., Basinski J., Farhi P., et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. JClin Psychiatry 2004, 65(12):1634-1641.
48. Kok R.M., Nolen W.A., Heeren T.J. Outcome of late-life depression after 3 years of sequential treatment. Acta Psychiatr Scand 2009, 119(4):274-281.
49. Ribeiz S., Avila R., Martins C.B., et al. Validation of a treatment algorithm for major depression in older Brazilian sample. Int J Geriatr Psychiatry 2013, 28(6):647-653.
50. Buchanan D., Tourigny-Rivard M.F., Cappeliez P., et al. National guidelines for seniors' mental health: the assessment and treatment of depression. Can J Psychiatry 2006, 9(Suppl 2):S52-S58.
51. Canadian Coalition for Senior's Mental Health. National guidelines for seniors' mental health - the assessment and treatment of depression. 2006. Available at: Accessed April 5, 2014. http://www.ccsmh.ca/en/projects/depression.cfm.
52. Alexopoulos G.S., Katz I.R., Reynolds C.F., et al. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. JPsychiatr Pract 2001, 7(6):361-376.
53. Mazeh D., Shahal B., Aviv A., et al. Arandomized single-blind comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007, 22:371-375.
54. Fava M., Alpert J., Nierenberg A., et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. JClin Psychopharmacol 2002, 22(4):379-387.
55. Quitkin F.M., Petkova E., McGrath P.J., et al. When should a trial of fluoxetine for major depression be declared failed?. Am J Psychiatry 2003, 160(4):734-740.
56. Rush A., Trivedi M., Wisniewski S., STAR*D Study Team, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEngl J Med 2006, 354:1231-1242.
57. Trivedi M., Fava M., Wisniewski S., STAR*D Study Team, et al. Medication augmentation after the failure of SSRIs for depression. NEngl J Med 2006, 354:1243-1252.
58. Thase M., Friedman E., Biggs M., et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007, 164:739-752.
59. Rush A., Wisniewski S., Warden D., et al. Selecting among second-step antidepressant medication monotherapies: are clinical, demographic, or first-step treatment results informative?. Arch Gen Psychiatry 2008, 65:870-880.
60. Posternak M.A., Baer L., Nierenberg A.A., et al. Response rates to fluoxetine in subjects who initially show no improvement. JClin Psychiatry 2011, 72(7):949-954.
61. Cooper C., Katona C., Lyketsos K., et al. Asystematic review of treatments for refractory depression in older people. Am J Psychiatry 2011, 168(7):681-688.
62. Mulsant B.H., Houck P.R., Gildengers A.G., et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression?. JClin Psychopharmacol 2006, 26(2):113-120.
63. Sackeim H.A., Roose S.P., Lavori P.W. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biol Psychiatry 2006, 59(6):483-492.
64. Schiff G.D., Galanter W.L., Duhig J., et al. Principles of conservative prescribing. Arch Intern Med 2011, 171(16):1433-1440.
65. Reynolds C.F., Dew M.A., Martire L.M., et al. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry 2010, 25(11):1134-1141.
66. Dombrovski A.Y., Mulsant B.H. ECT: the preferred treatment for severe depression in late life. Int Psychogeriatr 2007, 19(1):10-14.
67. Blumberger D.M., Mulsant B.H., Fitzgerald P.B., et al. Arandomized double-blind sham controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry 2012, 13(6):423-435.
68. Reynolds C.F., Dew M.A., Pollock B.G., et al. Maintenance treatment of major depression in old age. NEngl J Med 2006, 354(11):1130-1138.
69. US Food and Drug Administration. FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: Accessed April 12, 2014. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
70. Zivin K., Pfeiffer P.N., Bohnert A.S., et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013, 170(6):642-650.
71. Porsteinsson A.P., Drye L.T., Pollock B.G., CitAD Research Group, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014, 311(7):682-691.
72. Mulsant B.H. Challenges of the treatment of neuropsychiatric symptoms associated with dementia. Am J Geriatr Psychiatry 2014, 22(4):317-320.
73. Physician Drug Reference. Drug Summary - Cymbalta (duloxetine hydrochloride). 2014. Available at: Accessed April 14, 2014. http://www.pdr.net/drug-summary/cymbalta?druglabelid=288%26id=2223.
74. Schueler Y.B., Koesters M., Wieseler B., et al. Asystematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011, 123(4):247-265.
75. Cipriani A., Koesters M., Furukawa T.A., et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012, (10). CD006533.
76. Rocha F.L., Fuzikawa C., Riera R., et al. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. JClin Psychopharmacol 2012, 32(2):278-281.
77. Rajji T.K., Mulsant B.H., Lotrich F.E., et al. Use of antidepressants in late-life depression. Drugs Aging 2008, 25(10):841-853.
78. Chew M.L., Mulsant B.H., Pollock B.G., et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008, 56(7):1333-1341.
79. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60(4):616-631.
80. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. JAffect Disord 2000, 58(1):19-36.
81. Wilson K., Mottram P. Acomparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004, 19(8):754-762.
82. Machado M., Iskedjian M., Ruiz I., et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006, 22(9):1825-1837.
83. von Wolff A., Hölzel L.P., Westphal A., et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. JAffect Disord 2013, 144(1-2):7-15.
84. Sheffrin M., Driscoll H.C., Lenze E.J., et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. JClin Psychiatry 2009, 70(2):208-213.
85. Steffens D.C., Nelson J.C., Eudicone J.M., et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry 2011, 26(6):564-572.
86. Katila H., Mezhebovsky I., Mulroy A., et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 2013, 21(8):769-784.